Holen Sie sich die Stockscreener-App
1.14
3.39%
-0.04
Handel nachbörslich:
1.22
0.08
+7.02%
Schlusskurs vom Vortag:
$1.18
Offen:
$1.18
24-Stunden-Volumen:
452.26K
Relative Volume:
0.68
Marktkapitalisierung:
$96.45M
Einnahmen:
$100.56M
Nettoeinkommen (Verlust:
$-119.05M
KGV:
-0.9268
EPS:
-1.23
Netto-Cashflow:
$-231.16M
1W Leistung:
+23.90%
1M Leistung:
-11.63%
6M Leistung:
-76.05%
1J Leistung:
-76.30%
1-Tages-Spanne:
$1.13
$1.195
1-Wochen-Bereich:
$0.904
$1.24
52-Wochen-Spanne:
$0.87
$6.78
Alector Inc Stock (ALEC) Company Profile
Firmenname
Alector Inc
Sektor
Branche
Telefon
415-231-5660
Adresse
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
Vergleichen Sie ALEC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.14 | 96.45M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Alector Inc Stock (ALEC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-11-29 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-26 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-09-25 | Eingeleitet | Goldman | Sell |
| 2023-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-13 | Eingeleitet | Goldman | Sell |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-27 | Eingeleitet | William Blair | Outperform |
| 2021-01-15 | Fortgesetzt | BofA Securities | Buy |
| 2020-06-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-19 | Eingeleitet | Stifel | Buy |
| 2019-11-21 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-03-04 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Alector Inc Aktie (ALEC) Neueste Nachrichten
Following a 75% decline over last year, recent gains may please Alector, Inc. (NASDAQ:ALEC) institutional owners - simplywall.st
There is no way Alector Inc (ALEC) can keep these numbers up - Sete News
A Guide To The Risks Of Investing In Alector Inc (ALEC) - knoxdaily.com
ALEC’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Neogenomics Inc (NEO) Stock’s Detailed Analysis - Marketing Sentinel
Alector Inc (ALEC): What Makes The Stock Good? - Marketing Sentinel
Gentherm Inc Is A Buy Small Cap Stock: Analysts - Marketing Sentinel
Alector, Inc. (NASDAQ:ALEC) Holdings Cut by JPMorgan Chase & Co. - Defense World
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment - Yahoo Finance
What Analysts Were Expecting After Alector Inc (NASDAQ: ALEC) fell -5.95% - Stocksregister
Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101 - marketscreener.com
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease - GlobeNewswire
Alector (ALEC) Completes Enrollment for Alzheimer's Drug Trial | ALEC Stock News - GuruFocus
Major Milestone: Alector's Innovative Alzheimer's Drug Trial Hits Full Enrollment Ahead of Schedule - Stock Titan
Alector stock hits 52-week low at $0.99 amid sharp decline By Investing.com - Investing.com South Africa
Alector stock hits 52-week low at $0.99 amid sharp decline - Investing.com India
Alector, Inc. (NASDAQ:ALEC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Finance Watch: As Stocks Tumble, Offerings Slow, Financial Alternatives Rise - insights.citeline.com
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
Brokerages Set Alector, Inc. (NASDAQ:ALEC) Price Target at $3.50 - Defense World
Alector stock hits 52-week low at $1.24 amid market challenges - Investing.com
Charles Schwab Investment Management Inc. Reduces Stock Position in Alector, Inc. (NASDAQ:ALEC) - Defense World
Alector, Inc. (NASDAQ:ALEC) Shares Sold by Charles Schwab Investment Management Inc. - The AM Reporter
Alector Announces Resignation of Chief Medical Officer - TipRanks
Alector Appoints New Chief Medical Officer - MarketScreener
Alector Provides Executive Leadership Update - The Manila Times
Alector Names Neurology Expert as CMO Amid Crucial Phase 3 Dementia Trial - Stock Titan
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce - BioSpace
Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Alector stock hits 52-week low at $1.29 amid sharp annual decline - Investing.com Australia
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments By Investing.com - Investing.com South Africa
Alector at Virtual CNS Forum: Advancing Neurodegenerative Treatments - Investing.com
Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point (NASDAQ:ALEC) - Seeking Alpha
Mizuho’s latest rating for ALEC stock - Knox Daily
Alector at Leerink Global Healthcare Conference: Strategic Advances in Neurodegeneration - Investing.com India
Alector announces workforce reduction to cut costs By Investing.com - Investing.com Australia
Alector announces workforce reduction to cut costs - Investing.com
Alector to Cut 13% of Workforce - MarketWatch
Have Alector Insiders Been Selling Stock? - simplywall.st
Alector, Inc. (NASDAQ:ALEC) Receives $3.75 Consensus Target Price from Analysts - Defense World
Alector assumed with an Underweight at Morgan Stanley - TipRanks
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies - Investing.com India
Alector at TD Cowen Conference: Advancing Neurodegenerative Therapies By Investing.com - Investing.com UK
Alector Executives Sell Shares to Satisfy Tax Obligations - TradingView
Alector stock hits 52-week low at $1.54 amid sharp annual decline - Investing.com Australia
HC Wainwright Brokers Raise Earnings Estimates for Alector - The AM Reporter
Alector stock hits 52-week low at $1.54 amid sharp annual decline By Investing.com - Investing.com South Africa
Finanzdaten der Alector Inc-Aktie (ALEC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Alector Inc-Aktie (ALEC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | Chief Executive Officer |
Mar 03 '25 |
Sale |
1.47 |
40,330 |
59,176 |
2,466,744 |
| GRASSO MARC | Chief Financial Officer |
Mar 03 '25 |
Sale |
1.47 |
18,091 |
26,547 |
312,560 |
| Romano Gary | Chief Medical Officer |
Mar 03 '25 |
Sale |
1.47 |
16,306 |
23,927 |
332,977 |
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):